Loading patent…
AssigneeValipharma
InventorsAnnamari Ranki, Sonja Hahtola, Leena Karenko, Soile Tuomela, Riitta Lahesmaa, Kai J.E. Krohn
Estimating the term…
The present invention relates to the fields of genetics and oncology and provides methods for detecting cutaneous T-cell lymphomas (CTCL) or susceptibility to CTCL. Specifically, the present invention relates to a novel method for the diagnosis and follow-up of CTCL or CTCL subtype, the method comprising determination of expression of one or more genes, gene fragments or gene products. The present invention further relates to a novel method of detecting the response to CTCL therapy, the method comprising determining expression of one or more genes or gene fragments or gene products in a biological sample. The present invention further relates to a novel method of developing or improving CTCL therapy or developing anti-CTCL medicament, the method comprising screening agents affecting one or several of the genes or gene products. The present invention further relates to a novel method of treating CTCL patients, the method comprising affecting one or several of the genes or gene products. The present invention further relates to a novel test kit, the kit comprising the necessary means for detecting one or more genes, gene fragments or gene products. The present invention also relates to a use of one or more genes, gene fragments or gene products for determination, diagnosis or follow-up of CTCL or CTCL subtype and for detection of the response to CTCL therapy. The present invention also relates to a use of one or more target molecules for CTCL therapy or for the preparation of a medicament for treating CTCL.
A method of detecting cutaneous T-cell lymphomas (CTCL) or susceptibility to CTCL, characterized by determining expression of one or more genes, gene fragments or gene products selected from the group comprising MS4A4A, NKG7, IL7R, CD52, TBX21, SCYA5, and LIR9 in a biological sample, whereby under- or overexpression of one or more of said genes, gene fragments or gene products indicates CTCL or susceptibility to CTCL.
A method for the diagnosis and follow-up of CTCL, characterized by determining expression of one or more genes, gene fragments or gene products selected from the group comprising MS4A4A, NKG7, IL7R, CD52, TBX21, SCYA5, and LIR9 in a biological sample, whereby under- or overexpression of one or more of said genes, gene fragments or gene products indicates CTCL or susceptibility to CTCL.
A method for the diagnosis and follow-up of CTCL subtype, characterized by determining expression of one or more genes, gene fragments or gene products selected from the group comprising MS4A4A, NKG7, IL7R, CD52, TBX21, SCYA5, and LIR9 in a biological sample, whereby under- or overexpression of one or more of said genes, gene fragments or gene products indicates CTCL subtype or susceptibility to CTCL subtype.
A method of detecting the response to therapy of CTCL, characterized by determining expression of one or more genes or gene fragments or gene products selected from the group comprising MS4A4A, NKG7, IL7R, CD52, TBX21, SCYA5, and LIR9 in a biological sample, whereby normalization of under- or overexpression of one or more of said genes, gene fragments or gene products indicates response of CTCL therapy.
A method comprising use of one or more genes, gene fragments or gene products selected from the group comprising MS4A4A, NKG7, IL7R, CD52, TBX21, SCYA5, and LIR9 for determination of CTCL.
A method comprising use of one or more genes, gene fragments or gene products selected from the group comprising MS4A4A, NKG7, IL7R, CD52, TBX21, SCYA5, and LIR9 for the diagnosis or follow-up of CTCL.
A method comprising use of one or more genes, gene fragments or gene products selected from the group comprising MS4A4A, NKG7, IL7R, CD52, TBX21, SCYA5, and LIR9 for the diagnosis or follow-up of CTCL subtype.
A method comprising use of one or more genes, gene fragments or gene products selected from the group comprising MS4A4A, NKG7, IL7R, CD52, TBX21, SCYA5, and LIR9 for detection of the response to CTCL therapy.
A method comprising use of one or more genes, gene fragments or gene products selected from the group comprising MS4A4A, NKG7, IL7R, CD52, TBX21, SCYA5 and LIR9 as target molecules for therapy of CTCL.
A method of developing or improving CTCL therapy, characterized by screening agents affecting one or several of the genes or gene products selected from the group comprising MS4A4A, NKG7, IL7R, CD52, TBX21, SCYA5, and LIR9.
A method of developing anti-CTCL medicament, characterized by screening agents affecting one or several of the genes or gene products selected from the group comprising MS4A4A, NKG7, IL7R, CD52, TBX21, SCYA5, and LIR9.
A method of treating CTCL patients, characterized by affecting one or several of the genes or gene products selected from the group comprising MS4A4A, NKG7, IL7R, CD52, TBX21, SCYA5, and LIR9.
Dependencies are inferred from the claim text.